Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al

Ítems similars

• Reply to Jorgensen, et al
  per: Titanji, Boghuma K, et al.
  Publicat: (2020)
• Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
  per: Titanji, Boghuma K, et al.
  Publicat: (2020)
• In Response to “Coagulopathy of Coronavirus Disease 2019”
  per: Ng, Jensen, et al.
  Publicat: (2020)
• Coagulopathy of Coronavirus Disease 2019
  per: Iba, Toshiaki, et al.
  Publicat: (2020)
• Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection
  per: Titanji, Boghuma, et al.
  Publicat: (2020)